Actinium Pharmaceuticals, Inc. 10-Q

ITEM 5. OTHER INFORMATION. On July 26, 2021, Dale Ludwig resigned as the Company’s Chief Scientific and Technology Officer. Dr. Ludwig’s resignation is not the result of any disagreement with the Company or its Board of Directors or any matter relating to the Company’s operations, policies, or practices. ITEM 6. EXHIBITS Copies of the following documents are included as exhibits to this report pursuant to Item 601 of Regulation S-K. Exhibit No. Title of Document Location 3.1 Certificate of Incorporation of Actinium Pharmaceuticals, Inc. (incorporated by reference to Exhibit 3.1 of the Company’s Form 8-K filed with the SEC on April 17, 2013). 3.2 Certificate of Amendment to Certificate of Incorporation, as amended, filed January 7, 2014 (incorporated by reference to Exhibit 3.5 to Form S-1 filed on January 31, 2014). 3.3 Certificate of Amendment to Certificate of Incorporation, as amended, filed February 3, 2014. (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 7, 2014). 3.4 Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2015 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on March 4, 2015). 3.5 Certificate of Amendment to Certificate of Incorporation, as amended, filed on February 26, 2018 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on February 26, 2018). 3.6 Certificate of Amendment to Certificate of Incorporation, as amended, filed on March 6, 2019 (incorporated by reference to Exhibit 3.7 to Form 10-K filed on March 15, 2019). 3.7 Certificate of Amendment to Certificate of Incorporation, as amended, filed on June 16, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on June 16, 2020). 3.8 Certificate of Amendment to Certificate of Incorporation, as amended, filed on August 10, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on August 14, 2020). 3.9 Amended and Restated Bylaws, dated August 8, 2018 (incorporated by reference to Exhibit 3.1 to Form 10-Q filed on August 9, 2018). 3.10 Amendment to Amended and Restated Bylaws, dated May 7, 2020 (incorporated by reference to Exhibit 3.1 to Form 8-K filed on May 5, 2020). 31.1 Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Attached 31.2 Certification of the Principal Financial and Accounting Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002. Attached 32.1 Certification of the Chief Executive Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* Attached 32.2 Certification of the Principal Financial and Accounting Officer pursuant to U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002* Attached 101.INS Inline XBRL Instance Document Attached 101.SCH Inline XBRL Taxonomy Extension Schema Document Attached 101.CAL Inline XBRL Taxonomy Calculation Linkbase Document Attached 101.DEF Inline XBRL Taxonomy Extension Definition Linkbase Document Attached 101.LAB Inline XBRL Taxonomy Label Linkbase Document Attached 101.PRE Inline XBRL Taxonomy Presentation Linkbase Document Attached 104 Cover Page Interactive Data file (formatted as Inline XBRL and contained in Exhibit 101) Attached * The Exhibit attached to this Form 10-Q shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to liability under that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. 56 SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. ACTINIUM PHARMACEUTICALS, INC. Date: July 30, 2021 By: /s/ Sandesh Seth Sandesh Seth Chairman and Chief Executive Officer (Duly Authorized Officer and Principal Executive Officer) By: /s/ Steve O’Loughlin Steve O’Loughlin Chief Financial Officer (Duly Authorized Officer and Principal Financial and Accounting Officer) 57